Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New test aims to stop unnecessary antibiotics for respiratory infections

NCT ID NCT06070688

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a new diagnostic tool that helps doctors quickly tell if a respiratory infection is caused by bacteria or a virus. The goal is to see if using this test leads to better treatment decisions, fewer unnecessary antibiotics, and lower healthcare costs. About 100 adults with early symptoms of a respiratory infection will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2023

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria for main study population : * Current disease duration ≤ 7 days * Temperature ≥ 37.8°C (100°F) or tactile fever, noted at least once within the last 7 days * Clinical suspicion of bacterial or viral respiratory tract infection (RTI) Exclusion Criteria for main study population: * Systemic antibiotics taken up to 48 hours prior to presentation * Outpatient steroids taken within 48 hours prior to presentation * Suspicion and/or confirmed diagnosis of infectious gastroenteritis/colitis * Inflammatory disease * Congenital immune deficiency (CID) * A proven or suspected infection on the presentation with Mycobacterial, parasitic or fungal (e.g., Candida, Histoplasma, Aspergillus) pathogen * Human immunodeficiency virus(HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection (self-declared or known from medical records) * Major trauma and/or burns in the last 7 days * Major surgery in the last 7 days * Pregnancy - Self reported or medically confirmed * Active malignancy - Cancer diagnosed within the previous six months, recurrent, regionally advanced, or metastatic cancer, cancer for which treatment had been administered within six months, or hematological cancer that is not in complete remission. * Current treatment with immune-suppressive or immune-modulating therapies, at some point in the past 10 days * Hemodynamically unstable (require life-saving interventions such as vasopressors) * Patients transferred from another facility who already have a differentiated respiratory illness (known diagnosis e.g., culture positive results) * Consider unsuitable for the study by the study team Inclusion Criteria for Subgroup: * Written informed consent must be obtained from the patient or his/her legal guardian * Current disease duration ≤ 7 days * Clinical suspicion of bacterial or viral sepsis based on 2 or more SIRS criteria OR Clinical suspicion of bacterial or viral respiratory tract infection (RTI) AND temperature ≥ 37.8°C (100°F) or tactile fever, noted at least once within the last 7 days Patients fulfilling one or more of the following exclusion criteria from the main group are eligible for the subgroup cohort: * Systemic antibiotics taken up to 48 hours prior to presentation * Outpatient steroids taken within 48 hours prior to presentation * Suspicion and/or confirmed diagnosis of infectious gastroenteritis/colitis * Inflammatory disease (e.g., IBD, SLE, RA, other vasculitis) * Congenital immune deficiency (CID) * A proven or suspected infection on the presentation with Mycobacterial (e.g., MAC, MABC), parasitic or fungal (e.g., Candida, Histoplasma, Aspergillus) pathogen * HIV, HBV, or HCV infection (self-declared or known from medical records) * Major trauma and/or burns in the last 7 days * Major surgery in the last 7 days * Pregnancy - Self reported or medically confirmed * Active malignancy of a solid tumor - Cancer diagnosed within the previous six months, recurrent, regionally advanced, or metastatic cancer, cancer for which treatment had been administered within six months, or hematological cancer that is not in complete remission * Current treatment with immune-suppressive or immune-modulating therapies, at some point in the past 10 days * Hemodynamically unstable (require life-saving interventions such as vasopressors) * Patients transferred from another facility who already have a differentiated respiratory illness (known diagnosis e.g., culture positive results)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Respiratory tract infections are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The University of Texas Health Science Center at Houston

    RECRUITING

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.